Development and application of Hsp90 inhibitors.
Heat shock protein 90 has emerged as an important target in several diseases. The present review will discuss our understanding of the role played by Hsp90 in regulating and maintaining the transformed phenotype in cancers and neurodegenerative diseases, as well as recent findings on its roles in fungal and viral infections. It will also update the reader on the preclinical development and clinical translation of Hsp90 inhibitors.
Solit
David B
DB
Department of Medicine and the Human Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, United States.
Chiosis
Gabriela
G
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy; D015195:Drug Design; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D019636:Neurodegenerative Diseases / Q000188:drug therapy; D014777:Virus Diseases / Q000188:drug therapy
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D018841:HSP90 Heat-Shock Proteins